Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TC-5214 adjunctive therapy in major depressive disorder with inadequate antidepressant response
2010-024137-22Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmecamylamine in major depressive disorder (MDD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in MADRS total score. Started Feb 2011; status: terminated.
02
Drugs
dexmecamylamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-024137-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024137-22.